SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lehtonen Marko)
 

Sökning: WFRF:(Lehtonen Marko) > Plasma and cerebros...

  • Kumpulainen, Elina (författare)

Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children

  • Artikel/kapitelEngelska2010

Förlag, utgivningsår, omfång ...

  • 2010-09-14
  • Wiley,2010
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-134562
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-134562URI
  • https://doi.org/10.1111/j.1365-2125.2010.03720.xDOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Flurbiprofen is a commonly used non-steroidal anti-inflammatory drug in children to treat pain and fever. There is limited information on the pharmacokinetics of flurbiprofen in children and no data on the cerebrospinal fluid permeation of flurbiprofen. WHAT THIS STUDY ADDS Our population pharmacokinetic model indicates that weight-based dosing of flurbiprofen is appropriate in children older than 6 months. The bioavailability of oral flurbiprofen syrup is high, 71-91%, and thus, the oral syrup provides accurate dosing in paediatric patients. Cerebrospinal fluid concentrations of flurbiprofen are markedly higher than the unbound plasma concentrations. AIMS This study was designed to characterize paediatric pharmacokinetics and central nervous system exposure of flurbiprofen. METHODS The pharmacokinetics of flurbiprofen were studied in 64 healthy children aged 3 months to 13 years, undergoing surgery with spinal anaesthesia. Children were administered preoperatively a single dose of flurbiprofen intravenously as prodrug (n = 27) or by mouth as syrup (n = 37). A single cerebrospinal fluid (CSF) sample (n = 60) was collected at the induction of anaesthesia, and plasma samples (n = 304) before, during and after the operation (up to 20 h after administration). A population pharmacokinetic model was built using the NONMEM software package. RESULTS Flurbiprofen concentrations in plasma were well described by a three compartment model. The apparent bioavailability of oral flurbiprofen syrup was 81%. The estimated clearance (CL) was 0.96 l h-1 70 kg-1. Age did not affect the clearance after weight had been included as a covariate. The estimated volume of distribution at steady state (V-ss) was 8.1 l 70 kg-1. Flurbiprofen permeated into the CSF, reaching concentrations that were seven-fold higher compared with unbound plasma concentrations. CONCLUSIONS Flurbiprofen pharmacokinetics can be described using only weight as a covariate in children above 6 months, while more research is needed in neonates and in younger infants.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Valitalo, Pyry (författare)
  • Kokki, Merja (författare)
  • Lehtonen, Marko (författare)
  • Hooker, AndrewUppsala universitet,Institutionen för farmaceutisk biovetenskap(Swepub:uu)ancho179 (författare)
  • Ranta, Veli-Pekka (författare)
  • Kokki, Hannu (författare)
  • Uppsala universitetInstitutionen för farmaceutisk biovetenskap (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:British Journal of Clinical Pharmacology: Wiley70:4, s. 557-5660306-52511365-2125

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy